Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy | Hematology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy

Educational Objective
To determine risk factors for development of delayed neurotoxicity after treatment with chimeric antigen receptor T cells.
1 Credit CME
Key Points

Question  Which patients are at risk for delayed neurotoxicity after treatment with chimeric antigen receptor T cells?

Findings  In this diagnostic/prognostic study of 204 adults receiving axicabtagene ciloleucel for relapsed or refractory lymphoma, clinical and laboratory markers identified as risk factors for the subsequent development of neurotoxicity were used to create a prognostic model that had a sensitivity of 82% and a specificity of 70% when tested on an internal validation cohort for predicting which patients develop neurologic toxicity.

Meaning  Early identification of risk of neurotoxicity may allow for more appropriate triage and anticipatory care of patients receiving chimeric antigen receptor T-cell therapy.

Abstract

Importance  Chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory hematologic malignant neoplasm causes severe neurologic adverse events ranging from encephalopathy and aphasia to cerebral edema and death. The cause of neurotoxicity is incompletely understood, and its unpredictability is a reason for prolonged hospitalization after CAR T-cell infusion.

Objective  To identify clinical and laboratory parameters predictive of neurotoxicity and to develop a prognostic score associated with its risk.

Design, Setting, and Participants  This single-center diagnostic/prognostic accuracy study was conducted at Brigham and Women’s Hospital/Dana Farber Cancer Institute from April 2015 to February 2020. A consecutive sample of all patients undergoing CAR T-cell therapy with axicabtagene ciloleucel for relapsed or refractory lymphoma were assessed for inclusion (n = 213). Patients who had previously received CAR T cells or who were treated for mantle cell lymphoma were excluded (n = 9). Patients were followed up for a minimum of 30 days from the date of CAR T-cell infusion.

Main Outcomes and Measures  The primary outcomes were measures of performance (accuracy, sensitivity, specificity, area under the curve) of a diagnostic tool to predict the occurrence of CAR-associated neurotoxicity, as graded by the Common Terminology Criteria for Adverse Events criteria.

Results  Two hundred four patients (127 men [62.2%]; mean [SD] age, 60.0 [12.1] years) were included in the analysis, of which 126 (61.8%) comprised a derivation cohort and 78 (38.2%), an internal validation cohort. Seventy-three patients (57.9%) in the derivation cohort and 45 patients (57.7%) in the validation cohort experienced neurotoxicity. Clinical and laboratory values obtained early in admission were used to develop a multivariable score that can predict the subsequent development of neurotoxicity; when tested on an internal validation cohort, this score had an area under the curve of 74%, an accuracy of 77%, a sensitivity of 82%, and a specificity of 70% (positive:negative likelihood ratio, 2.71:0.26).

Conclusions and Relevance  The score developed in this study may help predict which patients are likely to experience CAR T-cell–associated neurotoxicity. The score can be used for triaging and resource allocation and may allow a large proportion of patients to be discharged from the hospital early.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Daniel B. Rubin, MD, PhD, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 175 Cambridge St, Ste 300, Boston, MA 02114 (drubin4@partners.org).

Accepted for Publication: April 27, 2020.

Published Online: August 10, 2020. doi:10.1001/jamaneurol.2020.2703

Author Contributions: Drs Rubin and Vaitkevicius had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Rubin, Basil Ali, Spendley, Vaitkevicius.

Acquisition, analysis, or interpretation of data: Rubin, Al Jarrah, Li, LaRose, Monk, Basil Ali, Nikiforow, Jacobson, Vaitkevicius.

Drafting of the manuscript: Rubin, Li, Vaitkevicius.

Critical revision of the manuscript for important intellectual content: Rubin, Al Jarrah, LaRose, Monk, Basil Ali, Spendley, Nikiforow, Jacobson, Vaitkevicius.

Statistical analysis: Rubin, Li.

Administrative, technical, or material support: LaRose, Monk, Basil Ali, Nikiforow, Jacobson, Vaitkevicius.

Supervision: Rubin, Nikiforow, Jacobson, Vaitkevicius.

Conflict of Interest Disclosures: Dr Rubin reports personal fees from Celgene/Bristol-Myers Squibb outside the submitted work. Ms Spendley reports other support for serving on an advisory board for Celgene outside the submitted work. Dr Nikiforow reports personal fees from Kite Pharma/Gilead Sciences and Novartis outside the submitted work. Jacobson reports personal fees from Kite Pharma, Novartis, Celgene, Bristol-Myers Squibb, Humanigen, Precision BioSciences, and Nkarta outside the submitted work. No other disclosures were reported.

References
1.
Brudno  JN , Kochenderfer  JN .  Toxicities of chimeric antigen receptor T cells: recognition and management.   Blood. 2016;127(26):3321-3330. doi:10.1182/blood-2016-04-703751PubMedGoogle ScholarCrossref
2.
Schuster  SJ , Svoboda  J , Chong  EA ,  et al.  Chimeric antigen receptor T Cells in refractory B-Cell lymphomas.   N Engl J Med. 2017;377(26):2545-2554. doi:10.1056/NEJMoa1708566PubMedGoogle ScholarCrossref
3.
Turtle  CJ , Hay  KA , Hanafi  LA ,  et al.  Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen Receptor-modified T cells after failure of ibrutinib.   J Clin Oncol. 2017;35(26):3010-3020. doi:10.1200/JCO.2017.72.8519PubMedGoogle ScholarCrossref
4.
Neelapu  SS , Locke  FL , Bartlett  NL ,  et al.  Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.   N Engl J Med. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447PubMedGoogle ScholarCrossref
5.
Neelapu  SS , Tummala  S , Kebriaei  P ,  et al.  Chimeric antigen receptor T-cell therapy: assessment and management of toxicities.   Nat Rev Clin Oncol. 2018;15(1):47-62. doi:10.1038/nrclinonc.2017.148PubMedGoogle ScholarCrossref
6.
Rubin  DB , Danish  HH , Ali  AB ,  et al.  Neurological toxicities associated with chimeric antigen receptor T-cell therapy.   Brain. 2019;142(5):1334-1348. doi:10.1093/brain/awz053PubMedGoogle ScholarCrossref
7.
Gutierrez  C , McEvoy  C , Mead  E ,  et al.  Management of the critically ill adult chimeric antigen receptor-t cell therapy patient: a critical care perspective.   Crit Care Med. 2018;46(9):1402-1410. doi:10.1097/CCM.0000000000003258PubMedGoogle ScholarCrossref
8.
Santomasso  BD , Park  JH , Salloum  D ,  et al.  Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia.   Cancer Discov. 2018;8(8):958-971. doi:10.1158/2159-8290.CD-17-1319PubMedGoogle ScholarCrossref
9.
Karschnia  P , Jordan  JT , Forst  DA ,  et al.  Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.   Blood. 2019;133(20):2212-2221. doi:10.1182/blood-2018-12-893396PubMedGoogle ScholarCrossref
10.
Hu  Y , Sun  J , Wu  Z ,  et al.  Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.   J Hematol Oncol. 2016;9(1):70. doi:10.1186/s13045-016-0299-5PubMedGoogle ScholarCrossref
11.
Lee  DW , Gardner  R , Porter  DL ,  et al.  Current concepts in the diagnosis and management of cytokine release syndrome.   Blood. 2014;124(2):188-195. doi:10.1182/blood-2014-05-552729PubMedGoogle ScholarCrossref
12.
Maude  SL , Frey  N , Shaw  PA ,  et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia.   N Engl J Med. 2014;371(16):1507-1517. doi:10.1056/NEJMoa1407222PubMedGoogle ScholarCrossref
13.
Grupp  SA , Kalos  M , Barrett  D ,  et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.   N Engl J Med. 2013;368(16):1509-1518. doi:10.1056/NEJMoa1215134PubMedGoogle ScholarCrossref
14.
Lee  DW , Kochenderfer  JN , Stetler-Stevenson  M ,  et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.   Lancet. 2015;385(9967):517-528. doi:10.1016/S0140-6736(14)61403-3PubMedGoogle ScholarCrossref
15.
Torre  M , Solomon  IH , Sutherland  CL ,  et al.  Neuropathology of a case with fatal CAR T-cell-associated cerebral edema.   J Neuropathol Exp Neurol. 2018;77(10):877-882. doi:10.1093/jnen/nly064PubMedGoogle ScholarCrossref
16.
Taraseviciute  A , Tkachev  V , Ponce  R ,  et al.  Chimeric antigen receptor T cell–mediated neurotoxicity in nonhuman primates.   Cancer Discov. 2018;8(6):750-763. doi:10.1158/2159-8290.CD-17-1368PubMedGoogle ScholarCrossref
17.
Gardner  RA , Finney  O , Annesley  C ,  et al.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.   Blood. 2017;129(25):3322-3331. doi:10.1182/blood-2017-02-769208PubMedGoogle ScholarCrossref
18.
Gust  J , Hay  KA , Hanafi  LA ,  et al.  Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.   Cancer Discov. 2017;7(12):1404-1419. doi:10.1158/2159-8290.CD-17-0698PubMedGoogle ScholarCrossref
19.
Turtle  CJ , Hanafi  LA , Berger  C ,  et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.   Sci Transl Med. 2016;8(355):355ra116. doi:10.1126/scitranslmed.aaf8621PubMedGoogle Scholar
20.
Gofshteyn  JS , Shaw  PA , Teachey  DT ,  et al.  Neurotoxicity after CTL019 in a pediatric and young adult cohort.   Ann Neurol. 2018;84(4):537-546. doi:10.1002/ana.25315PubMedGoogle ScholarCrossref
21.
Turtle  CJ , Hanafi  LA , Berger  C ,  et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.   J Clin Invest. 2016;126(6):2123-2138. doi:10.1172/JCI85309PubMedGoogle ScholarCrossref
22.
Bossuyt  PM , Reitsma  JB , Bruns  DE ,  et al; STARD Group.  STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies.   BMJ. 2015;351:h5527. doi:10.1136/bmj.h5527PubMedGoogle ScholarCrossref
23.
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 4.03. Updated June 14, 2010. Accessed July 1, 2020. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
24.
Brudno  JN , Maric  I , Hartman  SD ,  et al.  T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma.   J Clin Oncol. 2018;36(22):2267-2280. doi:10.1200/JCO.2018.77.8084PubMedGoogle ScholarCrossref
25.
Ali  SA , Shi  V , Maric  I ,  et al.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.   Blood. 2016;128(13):1688-1700. doi:10.1182/blood-2016-04-711903PubMedGoogle ScholarCrossref
26.
Raje  N , Berdeja  J , Lin  Y ,  et al.  Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.   N Engl J Med. 2019;380(18):1726-1737. doi:10.1056/NEJMoa1817226PubMedGoogle ScholarCrossref
27.
Hirayama  AV , Gauthier  J , Hay  KA ,  et al.  High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.   Blood. 2019;134(7):636-640. doi:10.1182/blood.2019000905PubMedGoogle ScholarCrossref
28.
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 5.0. Published November 27, 2017. Accessed July 1, 2020. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
29.
Lee  DW , Santomasso  BD , Locke  FL ,  et al.  ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.   Biol Blood Marrow Transplant. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close